Publikacje
Data | Program | Tytuł |
---|---|---|
wrz 2024 | Inflammatory diseases / PI3K |
Development of the telescoped flow Pd-catalyzed aerobic alcohol oxidation/reductive amination sequence in the synthesis of new phosphatidylinositide 3-kinase inhibitor (CPL302415) - PublicationsStanisław Michałek, Anna M. Maj, Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Krzysztof Wiśniewski, Marcin Zagozda, Mariola Stypik, Krzysztof Dubiela and Maciej Wieczorek - publication |
mar 2024 |
Exploring novel lipid nanoparticle compositions for effective delivery of mRNA - PostersEwelina Juszczyk, Karolina Fedko, Paweł Żero, Katarzyna Filip, Michał Mroczkiewicz, Mateusz Mach, Beata Zygmunt, Marta Mikońska, Joanna Hucz-Kalitowska, Małgorzata Choroś, Emilia Mróz, Maciej Wieczorek - publication |
|
mar 2024 | Inflammatory diseases / PI3K |
Development and optimization of a continuous flow ester reduction with LiAlH4 in the synthesis of a key intermediate for a PI3Kδ inhibitor (CPL302415) - PublicationsStanisław Michałek, Anna M. Maj, Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Marcin Zagozda, Zbigniew Ochal, Krzysztof Dubiela and Maciej Wieczorek - publication |
sty 2024 | Diabetes / GPR40 |
First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration - PublicationsKatarzyna Bazydło-Guzenda PhD, Katarzyna Jarus-Dziedzic PhD, Agnieszka Gierczak-Pachulska PhD, Paweł Buda PhD, Piotr J. Rudzki DSc, Katarzyna Buś-Kwaśnik PhD, Ewelina Juszczyk PhD, Ewa Tratkiewicz MSc, Daniel Rabczenko PhD, Agnieszka Segiet-Święcicka PhD, Maciej Wieczorek PhD - publication |
paź 2023 | Oncology |
CPL976, an innovative bispecific antibody targeting AXL and PD-L1 axis as a potential new anticancer therapeutic - PublicationsAgnieszka Bojko-Matuszek, Damian Kołakowski, Magdalena Bojko, Aleksandra Sowińska, Filip Mituła, Krzysztof Lacek, Delfina Popiel, Sebastian Kwiatkowski, Tomasz Kornatowski, Beata Kliszcz, Anna Jabłońska, Krzysztof Flis, Bartosz Wiernicki, Maciej Wieczorek , Jerzy Pieczykolan, Olga Abramczyk - poster |
paź 2023 | Oncology |
Design and preclinical evaluation of CPL976-MMAE - novel, potent AXL-PD-L1 bispecific antibody conjugated with MMAE in targeted anticancer therapy - PublicationsDelfina Popiel, Krzysztof Lacek, Anna Jabłońska, Aleksandra Sowińska, Agnieszka Bojko – Matuszek Damian Kołakowski, Filip Mituła, Sebastian Kwiatkowski, Magdalena Bojko, Tomasz Kornatowski, Beata Kliszcz, Tomasz Banach, Michał Górka, Jerzy Pieczykolan, Maciej Wieczorek, Olga Abramczyk - poster |
paź 2023 | Neuropsychiatry / PDE10A |
Repeated, 4-week dosing of CPL’36, a novel PDE10A inhibitor, does not induce tolerance to its antipsychotic-like action - PublicationsJ. Krzemień, A. Nikiforuk, N. Malikowska-Racia, A. Potasiewicz, J. Gołębiowska, E. Cyrano, K. Skowrońska, K. Górski, S. Kokhanovska, M. Wieczorek1, P. Popik, M. Matłoka - poster |
paź 2023 |
`Quality by Design (QbD) and Design of Experiments (DOE) as a Strategy for Tuning Lipid Nanoparticle Formulations for RNA Delivery - PublicationsLidia Gurba-Bryśkiewicz, Wioleta Maruszak, Damian A. Smuga, Krzysztof Dubiel, Maciej Wieczorek - publication |
|
wrz 2023 | Oncology / FGFR |
Fast Claisen condensation reaction optimization in a continuous flow reactor - PublicationsStanisław Michałek, Antoni Powała, Lidia Gurba-Bryśkiewicz, Natalia Piórkowska, Patrycja Olejkowska, Abdellah Yamani, Zbigniew Ochal, Krzysztof Dubiel, Maciej Wieczorek - publication |
lip 2023 | Neuropsychiatry |
Dual Piperidine-Based Histamine H3 and Sigma-1 Receptor Ligands in the Treatment of Nociceptive and Neuropathic Pain - PublicationsKatarzyna Szczepańska, Tadeusz Karcz*, Maria Dichiara, Szczepan Mogilski, Justyna Kalinowska-Tłuścik, Bogusław Pilarski, Arkadiusz Leniak, Wojciech Pietruś, Sabina Podlewska, Katarzyna Popiołek-Barczyk, Laura J. Humphrys, M. Carmen Ruiz-Cantero, David Reiner-Link, Luisa Leitzbach, Dorota Łażewska, Steffen Pockes, Michał Górka, Adam Zmysłowski, Thierry Calmels, Enrique J. Cobos, Agostino Marrazzo, Holger Stark, Andrzej J. Bojarski, Emanuele Amata and Katarzyna Kieć-Kononowicz - publication |
kwi 2023 | Inflammatory diseases / PI3K |
Tuning the Biological Activity of PI3Kδ Inhibitor by the Introduction of a Fluorine Atom Using the Computational Workflow - PublicationsWojciech Pietruś, Mariola Stypik, Marcin Zagozda, Martyna Banach, Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Arkadiusz Leniak, Rafał Kurczab, Zbigniew Ochal, Krzysztof Dubiel, Maciej Wieczorek
|
kwi 2023 | Oncology / FGFR |
ESMO TAT 2023 - Publications |
mar 2023 | Inflammatory diseases / PI3K |
Development and optimization of a continuous flow ester reduction with LiAlH4 in the synthesis of a key intermediate for a PI3Kδ inhibitor (CPL302415)† - PublicationsStanisław Michałek, Anna M. Maj, Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Marcin Zagozda, Zbigniew Ochal, Krzysztof Dubiel and Maciej Wieczorek |
lis 2022 | Inflammatory diseases / PI3K |
The design of experiments (DoE) in optimization of an aerobic flow Pd-catalyzed oxidation of alcohol towards an important aldehyde precursor in the synthesis of phosphatidylinositide 3-kinase inhibitor (CPL302415) - PublicationsStanisław Michałek, Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Marcin Zagozda, Anna M. Maj, Zbigniew Ochal, Krzysztof Dubiel, Maciej Wieczorek |
lis 2022 | Neuropsychiatry / PDE10A |
A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects - PublicationsMikolaj Matloka, Sylwia Janowska, Piotr Pankiewicz, Sofiya Kokhanovska, Tomasz Kos, Małgorzata Hołuj, Izabela Rutkowska-Wlodarczyk, Krzysztof Abramski, Monika Janicka, Piotr Jakubowski, Maciej Świątkiewicz, Marlena Welniak-Kaminska, Joanna Hucz-Kalitowska, Paulina Dera, Lukasz Bojarski, Paweł Grieb, Piotr Popik ,Maciej Wieczorek, Jerzy Pieczykolan |
paź 2022 | Inflammatory diseases / JAK/ROCK |
Implementation of QbD Approach to the Development of Chromatographic Methods for the Determination of Complete Impurity Profile of Substance on the Preclinical and Clinical Step of Drug Discovery Studies - PublicationsLidia Gurba-Bryskiewicz, Urszula Dawid, Damian A. Smuga, Wioleta Maruszak, Monika Delis, |
wrz 2022 | Oncology / FGFR |
FGFR1–4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer - Publicationsby Joanna Moes-Sosnowska,Monika Skupinska,Urszula Lechowicz,Ewa Szczepulska-Wojcik,Paulina Skronska,Adriana Rozy,Aneta Stepniewska,Renata Langfort,Piotr Rudzinski,Tadeusz Orlowski,Delfina Popiel,Aleksandra Stanczak,Maciej Wieczorek and Joanna Chorostowska-Wynimko |
sie 2022 | Inflammatory diseases / PI3K |
Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II—Benzimidazole Derivatives - PublicationsMariola Stypik,Stanisław Michałek ,Nina Orłowska,Marcin Zagozda,Maciej Dziachan,Martyna Banach,Paweł Turowski,Paweł Gunerka,Daria Zdżalik-Bielecka,Aleksandra Stańczak,Urszula Kędzierska,Krzysztof Mulewski,Damian Smuga,Wioleta Maruszak,Lidia Gurba-Bryśkiewicz,Arkadiusz Leniak,Wojciech Pietruś,Zbigniew Ochal,Mateusz Mach,Beata Zygmunt,Jerzy Pieczykolan,Krzysztof Dubiel, Maciej Wieczorek |
sie 2022 | Inflammatory diseases |
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I—Indole Derivatives - Publicationsby Mariola Stypik, Marcin Zagozda, Stanisław Michałek, Barbara Dymek,Daria Zdżalik-Bielecka, Maciej Dziachan, Nina Orłowska, Paweł Gunerka, Paweł Turowski, Joanna Hucz-Kalitowska, Aleksandra Stańczak, Paulina Stańczak, Krzysztof Mulewski , Damian Smuga, Filip Stefaniak, Lidia Gurba-Bryśkiewicz, Arkadiusz Leniak, Zbigniew Ochal, Mateusz Mach, Karolina Dzwonek |
maj 2022 | Oncology |
Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy - PublicationsAgata Mikolajczyk,Filip Mitula,ORCID,Delfina Popiel,Bozena Kaminska,Maciej Wieczorek and Jerzy Pieczykolan |
maj 2022 | Oncology |
Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy - PublicationsAgata Mikolajczyk, Filip Mitula, Delfina Popiel, Bozena Kaminska, Maciej Wieczorek, Jerzy Pieczykolan |
kwi 2022 | Neuropsychiatry / Esketamine |
Esketamine inhaled as dry powder : Pharmacokinetic, pharmacodynami can dsafety assessment in a preclinical study - PublicationsMikołaj Matłok, Sylwia Janowska, Anna Gajoss - Draus, Hubert Ziółkowski,Monika Janicka, Przemysław Perko, Kisło Kamila, Piotr Pankiewicza, Rafał Moszczyński-Pętkowski, Mateusz Mach, Paulina Dera, Krzysztof Abramski, Małgorzata Teska-Kamińska, Ewa Tratkiewicz, Maciej Wieczorek, Jerzy Pieczykolan;
|
lis 2021 | Oncology / FGFR |
p38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer - PublicationsIzabela Zarczynska , Monika Gorska-Arcisz , Alexander Jorge Cortez , Katarzyna Aleksandra Kujawa, Agata Małgorzata Wilk, Andrzej Cezary Skladanowski, Aleksandra Stanczak, Monika Skupinska , Maciej Wieczorek, Katarzyna Marta Lisowska , Rafal Sadej, Kamila Kitowska
|
lis 2021 | Neuropsychiatry |
CPL500036 - a novel inhibitor of phosphodiesterase 10A - attenuates parkinsonian-like and L-DOPA induced dyskinetic effects in 6-OHDA lesioned rats - PostersM. Matłoka, T. Lenda, K. Ossowska, K. Berghauzen-Maciejewska, D. Biała, A. Gajos-Draus, P. Pankiewicz, K. Mulewska, A. Janusz, D. Smuga, M. Górka, J. Pieczykolan, M. Wieczorek, J. Konieczny, Poster at Neuroscience 2021, 50th Annual Meeting 8-11 November |
wrz 2021 | Diabetes / GPR40 |
Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey - PublicationsKatarzyna Bazydło-Guzenda, Paweł Buda, Mateusz Mach, Jerzy Pieczykolan, Izabela Kozlowska, Michał Janiszewski, Ewa Drzazga, Jakub Dominowski, Hubert Ziolkowski, Maciej Wiezorek, Shayne Cox Gad
|
wrz 2021 | Diabetes / GPR40 |
Discovery and development of CPL207280 as new GPR40/FFA1 agonist - PublicationsMateusz Mach, Katarzyna Bazydło-Guzenda, Paweł Buda, Mikołaj Matłoka, Radosław Dzida, Filip Stelmach, Kinga Gałązka, Małgorzata Wąsińska - Kałwa, Damian Smuga, Dagmara Hołowińska, Urszula Dawid, Lidia Gurba-Bryśkiewicz, Krzysztof Wiśniewski, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek
|
wrz 2021 | Oncology / FGFR |
Analysis of fibroblast growth factor receptor 3 aberrations in bladder cancer, for enabling personalized and effective therapy based on FGFR inhibitor - PostersR. Sosnowski, D. Popiel, P. Gapska, M. Skupinska, P. Stajno, M. Sobieszek-Prochorec, M. Ligaj, T. Demkow, A. Stanczak, M. Wieczorek, J. Pieczykolan, Poster at European Society for Medical Oncology 16 - 21 Sep 2021 Paris, Virtual, France |
wrz 2021 | Neuropsychiatry / Esketamine |
Safety assessment of esketamine administration via dry powder inhaler in patients with treatment-resistant bipolar depression - PostersM. Wieczorek, S. Janowska, P. Gałecki, Poster at the 34th ECNP Congress, 2-5 October 2021, Lisbon, Portugal |
wrz 2021 | Neuropsychiatry / Esketamine |
Safety assessment of esketamine administered via dry powder inhaler in patients with treatment-resistant major depression - PostersS. Janowska, M. Wieczorek, P. Gałecki, Poster at the 34th ECNP Congress, 2-5 October 2021, Lisbon, Portugal |
wrz 2021 | Neuropsychiatry / Esketamine |
Inflammatory cytokine plasma levels correlation with MADRS score in patients with treatment-resistant major depression after dry-powder inhaled esketamine administration - PostersM. Matłoka, A. Gajos-Draus, I. Majkowska, S. Kokhanovska, P. Pankiewicz, S. Janowska, K. Wójcik, M. Wieczorek, J. Pieczykolan, Poster at the 34th ECNP Congress, 2-5 October 2021, Lisbon, Portugal |
wrz 2021 | Oncology / FGFR |
FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC) - PostersJ. Moes-Sosnowska, A. Rozy, M. Skupińska, U. Lechowicz, E. Szczepulska-Wojcik, R. Langfort, P. Rudzinski, T. Orlowski, D. Popiel, M. Wieczorek, A. Stanczak, J. Chorostowska-Wynimko, E-poster European Respiratory Society (ERS) 2021, 5–8 September 2021 |
wrz 2021 | Inflammatory diseases / PI3K |
Potent and selective indol-4-YL pyrazolo[1,5-a]pyrimidine-derived PI3Kδ inhibitors as potential candidates for treatment of copd and asthma - PostersStanisław Michałek, Mariola Stypik, Marcin Zagozda, Nina Orłowska, Martyna Banach, Urszula Kędzierska, Beata M. Zygmunt, Kamila Gala, Maciej Dziachan, Barbara Dymek, Daria Zdzalik, Paweł Gunerka, Paweł Turowski, Maria Bretner, Zbigniew Ochal, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek |
wrz 2021 | Inflammatory diseases / JAK/ROCK |
Novel benzimidazole-derived PI3Kδ inhibitors as highly potent drugs candidates for SLE and other inflammatory and autoimmune diseases - PostersMariola Stypik, Stanisław Michałek, Marcin Zagozda, Nina Orłowska, Martyna Banach, Urszula Kędzierska, Beata M. Zygmunt, Kamila Gala, Maciej Dziachan, Barbara Dymek, Daria Zdzalik, Paweł Gunerka, Paweł Turowski, Zbigniew Ochal, Maria Bretner, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek
|
sie 2021 | Neuropsychiatry |
Antiparkinsonian - like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease - PublicationsTomasz Lenda, Krystyna Ossowska, Klemencja Berghauzen-Maciejewska, Mikołaj Matłoka, Jerzy Pieczykolan, Maciej Wieczorek, Jolanta Konieczny |
sie 2021 | Diabetes / GPR40 |
CPL207280 - a novel GPR40/FFA1 - specific agonist shows a favorable safety profile and exerts anti-diabetic effects in type 2 diabetic animals - PublicationsKatarzyna Bazydlo-Guzenda, Pawel Buda, Mikolaj Matloka, Mateusz Mach, Filip Stelmach, Radoslaw Dzida, Damian Smuga, Joanna Hucz-Kalitowska, Malgorzata Teska-Kaminska, Varvara Vialichka, Krzysztof Dubiel, Bozena Kaminska, Maciej Wieczorek and Jerzy Pieczykolan. Molecular Pharmacology August 4, 2021 |
lip 2021 | Neuropsychiatry |
Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and screening for Novel TrkB Od Srthosteric Agonists - PublicationsPiotr Pankiewicz, Marcin Szybiński, Katarzyna Kisielewska, Filip Gołębiowski, Patryk Krzemiński, Izabela Rutkowska Włodarczyk, Rafał Moszczyński Pętkowski, Lidia Gurba Bryśkiewicz, Monika Delis, Krzysztof Mulewski, Damian Smuga, Jakub Dominowski, Artur Janusz, Michał Górka, Krzysztof Abramski, Agnieszka Napiórkowska, Marcin Nowotny, Krzysztof Dubiel, Katarzyna Kalita, Maciej Wieczorek, Jerzy Pieczykolan, Mikołaj Matłoka |
cze 2021 | Diabetes / GPR40 |
Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 agonist for First-in-Human Clinical Trial - PublicationsEwelina Juszczyk, Kamil Kisło, Paweł ̇Zero, Ewa Tratkiewicz, Maciej Wieczorek, Jadwiga Paszkowska, Grzegorz Banach, Marcela Wiater, Dagmara Hoc, Grzegorz Garbacz, Jaroslaw Sczodrok, Dorota Danielak |
kwi 2021 | Inflammatory diseases / JAK/ROCK |
A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus - PublicationsMaria Dulak-Lis, Anna Bujak, Kamila Gala, Martyna Banach, Urszula Kędzierska, Joanna Miszkiel, Joanna Hucz-Kalitowska, Michał Mroczkiewicz, Bartosz Stypik, Krzysztof Szymczak, Paweł Gunerka, Krzysztof Dubiel, Beata M. Zygmunt, Maciej Wieczorek, Jerzy S. Pieczykolan |
kwi 2021 | Oncology / FGFR |
MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells - PublicationsKitowska K., Gorska-Arcisz M., Antoun D., Zarczynska I., Czaplinska D., Szczepaniak A., Skladanowski C.A., Wieczorek M., Stanczak A., Skupinska M., Sadej R. |
sty 2021 | Oncology / FGFR |
RNA-Based Gene Alteration and Expression Analysis in Sq-NSCLC with known FGFR1 Amplification and Protein Expression Status - PostersJ. Moes-Sosnowska, A. Rozy, M. Skupinska, U. Lechowicz, E. Szczepulska-Wojcik,1 R. Langfort, P. Rudzinski, T. Orlowski, D. Popiel, M. Wieczorek, A. Stańczak, J. Chorostowska-Wynimko, Worldwide Virtual Event IASLC : World Conference on Lung Cancer 2020 ; January 2021 |
cze 2020 | Oncology / FGFR |
Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3) - PublicationsYamani A., Zdżalik-Bielecka D., Lipner j., Stańczak A., Piórkowska N., Stańczak P., Olejkowska P., Hucz-Kalitowska J., Magdycz M., Dzwonek K., Dubiel K., Lamparska-Przybysz M., Popiel D., Pieczykolan J., Wieczorek M. |
cze 2020 | Oncology / FGFR |
Preclinical characterization of CPL304110 as a potential selective inhibitor of Fibroblast Growth Factors 1/2/3 in solid cancers - PostersPopiel D., Mikołajczyk A., Skupińska M., Hucz-Kalitowska J., Stańczak P., Piorkowska N., Yamani A., Dubiel K., Stańczak A., Pieczykolan J., Wieczorek M.
|
cze 2020 | Oncology / FGFR |
Comparing different methods of FGFR1 aberrations analysis in squamous cell lung cancer (SQCLC) potential targeted therapy - PostersSkupińska M., Obtułowicz T., Moes-Sosnowska J., Rozy A., Szczepulska- Wójcik E., Langfort R., Chorostowska-Wynimko J., Stańczak A., Pieczykolan J., Wieczorek M., Popiel D.
|
cze 2020 | Oncology / FGFR |
Molecular profiling of Sq-NSCLC with enhanced FGFR1-4 and MET gene expression - NGS pilot study - PostersMoes-Sosnowska J., Szczepulska-Wojcik E., Rozy A., Langfort R., Rudzinski P., Orlowski T., Skupinska M., Popiel D., Wieczorek M., Stanczak A., Chorostowska-Wynimko J. |
cze 2020 | Diabetes / GPR40 |
Development of SR matrix tablet containing a new GPR40 agonist for first-in human clinical trial - PostersEwelina Juszczyk, Kamil Kisło, Paweł Żero, Ewa Tratkiewicz, Jadwiga Paszkowska, Dorota Danielak, Jarosław Szczodrok, Grzegorz Garbacz |
cze 2020 | Inflammatory diseases / PI3K |
Preclinical characterization of CPL302-253, a selective inhibitor of P13K, as the candidate for the inhalatory treatment and prevention of asthma - Publications |
mar 2020 | Neuropsychiatry / PDE10A |
The study of molecular changes induced by CPL500-036, a potential novel anti-dyskinetic drug, in 6-OHDA rat model of PD - PostersGajos-Draus A., Mulewski K., Górka M., Konieczny J., Lenda T., Ossowska K., Biala D., Kokhanovska S., Smuga D., Pieczykolan J., Wieczorek M, Matłoka M. |
lut 2020 | Neuropsychiatry |
The study of molecular changes induced by CPL500-036, a potential novel anti-dyskinetic drug, in 6-OHD rat model of PD - PostersGajos-Draus A., Mulewski K., Górka M., Konieczny J., Lenda T., Ossowska K., Biala D., Kokhanovska S., Smuga D., Pieczykolan J., Wieczorek M., Matłoka M. |
cze 2019 | Oncology / FGFR |
Efficacy study of Celon Pharma FGFR kinase inhibitor in two patient-derived tumour xenograft (PDTX) models - PostersHucz-Kalitowska J., Teska-Kamińska M., Stańczak A., Skupińska M., Mikołajczyk A., Pieczykolan J., Wieczorek M., |
cze 2019 | Neuropsychiatry / Esketamine |
Safety assessment of esketamine administered via dry powder inhalation in animals and humans during preclinical toxicology and phase I clinical study - PostersMatłoka M., Janowska J., Sierzputowska J., Jarus-Dziedzic K., Pieczykolan J., Wieczorek M. |
cze 2019 | Neuropsychiatry / Esketamine |
Safety and pharmacokinetic study of inhaled esketamine after a multiple dose in healthy volunteers - Posters |
cze 2019 | Neuropsychiatry / PDE10A |
Safety and pharmacokinetic study of phosphodiesterase 10A inhibitor ( CPPL500036 ) after a single dose in healthy volunteers - PostersJanowska S., Jarus-Dziedzic K., Sierzputowska J., Matłoka M., Wieczorek M. |
paź 2018 | Neuropsychiatry / Esketamine |
Safety and pharmacokinetics study of inhaled esketamine after a single dose in healthy volunteers - PostersJanowska S., Tratkiewicz E., Matłoka M., Perko P., Gaciarz M., Wieczorek M. |
paź 2018 | Diabetes / GPR40 |
Novel GPR40 agonist CPL-207-280 independently improves glycaemia and mitigates neuropathic pain in diabetic rodents - PostersPaweł Buda, Katarzyna Bazydło-Guzenda, Mateusz Mach, Filip Stelmach, Radosław Dzida, Joanna Hucz-Kalitowska, Małgorzata Teska-Kaminska, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek |
paź 2018 | Neuropsychiatry / PDE10A |
Novel and highly bioavailable PDE10A inhibitor activates cyclic nucleotides depending signaling in rat striatum - PostersPankiewicz P., Janowska S., Gajos-Draus A., Mozolewski P., Drzazga E., Kokhanovska S., Janicka M., Hucz-Kalitowska J., Świątkieicz M., Wełniak-Kamińska M., Fiedorowicz M., Grieb P., Pieczykolan J., Wieczorek M., Matłoka M.
|
wrz 2018 | Neuropsychiatry / Esketamine |
pharmacodynamics-of-s-ketamine-and-ketamine-racemate-in-rat-pfc-and-hp-after-dry-powder-inhalation-intratracheal-and-intravenous-administration - PostersKetamine High Dose Dry Powder Composition for Pulmonary Administration, Gajos-Draus A., Janowska S., Janicka M., Wieczorek M., Pieczykolan J., Matloka M. |
wrz 2018 | Neuropsychiatry / PDE10A |
cpl-500-036-02-novel-and-highly-bioavailable-pde10a-inhibitor-activates-cyclic-nucleotides-depending-signaling-in-rat-striatum - PostersPankiewicz P., Janowska S., Gajos-Draus A., Mozolewski P., Drzazga E., Janicka M., Hucz-Kalitowska J., Świątkiewicz M., Wełniak-Kamińska M., Fiedorowicz M. Grieb P., Pieczykolan J., Wieczorek M., Matłoka M. |
wrz 2018 | Neuropsychiatry / Esketamine |
safety-and-pharmacokinetics-study-of-inhaled-esketamine-after-a-single-dose-in-healthy-volunteers - PostersJanowska, S., Tratkiewicz, E., Matloka, M., Perko, P., Gaciarz, M., Urban, A., Wieczorek, M. |
lip 2018 | Neuropsychiatry / 5-HT6R |
Pyrroloquinoline scaffold-based 5-HT6R ligands: synthesis, quantum chemical and molecular dynamic studies, and influence of nitrogen atom position in thescaffold on affinity - PublicationsGrychowska, Rafał Kurczab, Paweł Śliwa, Grzegorz Satała, Krzysztof Dubiel, Mikołaj Matłoka, Rafał Moszczyński-Pętkowski, Jerzy Pieczykolan, Andrzej J. Bojarski, Paweł Zajdel Bioorganic & Medicinal Chemistry Volume 26, Issue 12, 23 July 2018, Pages 3588-3595 doi: 10.1016/j.bmc.2018.05.033 |
lip 2018 | Oncology / FGFR |
The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine - based chemotherapy - PostersSkupińska M., Jesiotr M., Chrom P., Mróz A., Cierniak S., Winiarek M., Wyrwicz L., Pieczykolan J., Wieczorek M., Stańczak A., Bodnar L. |
cze 2018 | Oncology |
Rational-based drug design of novel, highly potent MER inhibitors as potential treatment of cancers - PostersMikolajczyk A., Yamani A., Olejkowska P., Piorkowska N., Naitana M., Maliszewski P., Dubiel K., Pieczykolan J., wieczorek M., Stanczak A. |
cze 2018 | Oncology |
CPL-410-005, a novel ubiquitin-activating enzyme (UAE) inhibitor in preclinical evaluation as ananticancer treatment for solid tumours - PostersKozłowska D., Górnicka A., Stypik B., Mroczkiewicz M., Mikolajczyk A., Hucz-Kalitowska J.,Szwalbe A., Mulewski K., Smuga D., Dubiel K., Pieczykolan J., Wieczorek M., Stańczak A.
|
cze 2018 | Oncology / FGFR |
Analiza mutacji FGFR3 w grupie 116 pacjentów z niezaawansowaną postacią raka pęcherza moczowego - PostersGapska P., Sosnowski R., Stajno P., Ligaj M., Prochorec-Sobieszek M., Pieczykolan J., Wieczorek M., Demkow T., Stańczak A.
|
cze 2018 | Oncology / FGFR |
Search for predictive biomarkers of sensitivity/resistance against novel FGFR inhibitor using array-based comparative genomic hybridization(aCGH) and RNA sequencing (RNAseq)-preliminary results - PostersCortez A.J., Kujawa K.A., Tudrej P.A., Kitowska K., Sądej R., Student S., Klyszcz K., Lisowska K.M. |
cze 2018 | Neuropsychiatry / Esketamine |
Pyrroloquinoline scaffold-based 5-HT6R ligands: synthesis, quantum chemical and molecular dynamic studies and influence of nitrogen atom position in thescaffold on affinity - PublicationsBioorganic & Medicinal Chemistry doi: 10.1016/j.bmc.2018.05.033, |
cze 2018 | Neuropsychiatry / Esketamine |
LC-MS/MS chiral method for simultaneous determination of RS-ketamine and its metabolites in rat plasma and brain samples frpm pharmacokinetic studies - PostersJanicka M., Matłoka M., Mach M., Moszczyński-Pętkowski R., Pieczykolan J., Tratkiewicz E., Wieczorek M. |
cze 2018 | Neuropsychiatry / Esketamine |
Pharmacokinetic properties of S-ketamine and ketamine racemate after dry powder inhalation, intravenous and intratracheal administration in rats - PostersMatłoka M., Janowska S., Janicka M., Mach M., Moszczyński-Pętkowski R., Ziółkowski H., Draus A., Tratkiewicz E., Pieczykolan J., Wieczorek M. |
cze 2018 | Neuropsychiatry / Esketamine |
Pharmacodynamics of S-ketamine and ketamine racemate in rat PFC and HP after dry powder inhalation, intratracheal nd intravenous administration - PostersGajos- Draus A., Janowska S., Janicka M., Wieczorek M., Pieczykolan J., Matłoka M. |
cze 2018 | Diabetes / GPR40 |
Discovery of CPL 207-280CA, an effective and safe GPR40 agonist for the treatment of type 2 diabetes - PostersKatarzyna Bazydło, Paweł Buda, Mateusz Mach, Radosław Dzida, Filip Stelmach, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek |
maj 2018 | Neuropsychiatry / PDE10A |
Synthesis and characterization of novel classes of PDE10A inhibitors - 1H - 1,3-benzodiazoles and imidazo [1,2-a] pyrimidines - PublicationsRafał Moszczyński-Pętkowski, Jakub Majer, Małgorzata Borkowska, Łukasz Bojarski, Sylwia Janowska, Mikołaj Matłoka, Filip Stefaniak, Damian Smuga, Katarzyna Bazydło, Krzysztof Dubiel, Maciej Wieczorek, European Journal of Medicinal Chemistry |
maj 2018 | Neuropsychiatry / Esketamine |
Pharmacokinetic properties of S-ketamine and ketamine racemate after dry powder inhalation, intravenous and intratracheal administration in rats - PostersMatłoka M., Janowska S., Janicka M., Mach M., Moszczyński-Pętkowski R., Ziółkowski H., Draus A., Tratkiewicz E., Pieczykolan J., Wieczorek M. |
cze 2017 | Oncology |
Design and development of potent E1 ubiquitin activating enzyme inhibitor, CPL-410-005, as novel anticancer therapy - PostersStańczak A., Górnicka A., Stypik B., Mroczkiewicz M., Pieczykolan J., Dubiel K., Wieczorek M. |
cze 2017 | Oncology / FGFR |
Low consistency between FGFR1 gene amplification and protein expression in squamous cell lung cancer (SQCLC) - PostersChorostowska-Wynimko J., Skupinska M.M., Rozy A., Siewiera K., Szczepulska E., Langfort R., Rudzinski P., Orlowski T., Wieczorek M., Stanczak A. |
cze 2017 | Oncology / FGFR |
Ovarian cancer cells show enhanced response to the novel FGFR inhibitor CPL-304-110 - PostersKujawa K.A., Rusin A. Olbryt M., Tudrej P., Cortez A.J., Stanczak A., Wieczorek M., Lisowska K.M. |
cze 2016 | Neuropsychiatry |
The modulation of cyclic nucleotide dependent pathways in the rat striatum by CPL-500-036-02 - a phosphodiesterase 10A inhibitor - PostersSylwia Janowska, Piotr Pankiewicz, Maciej Świątkiewicz, Marlena Wełniak-Kamińska, Małgorzata Borkowska, Jakub Majer, Rafał Moszczyński-Pętkowki, Krzysztof Dubiel, Maciej Wieczorek, Mikołaj Matłoka |
maj 2016 | Neuropsychiatry / PDE10A |
Development of the novel and selective inhibitor of phosphodiesterase 10A-CPL-500-036-02 and exploring its mode of action - PostersMikołaj Matłoka, Katarzyna Bieganska, Sylwia Janowska, Piotr Pankiewicz, Katarzyna Kalita, Jerzy Pieczykolan, Leszek Kaczmarek, Maciej Wieczorek |
kwi 2016 | Neuropsychiatry / PDE10A |
The modulation of cyclicnucleotide dependent pathways in the rat striatum by CPL-500-036-02 - a phosphodiesterase 10a inhibitor. - PublicationsJanowska S, Pankiewicz P, Swiatkiewicz M, Welniak-Kaminska M, Borkowska M, Majer J, Moszczynski-Petkowski R, Dubiel K, Wieczorek M, Matloka M. |
paź 2015 | Inflammatory diseases / JAK/ROCK |
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors - PublicationsPawel Gunerka; Barbara Dymek; Aleksandra Stanczak; Anna Bujak; Paulina Grygielewicz; Pawel Turowski; Karolina Dzwonek; Monika Lamparska-Przybysz; Tadeusz Pietrucha; Maciej Wieczorek, European Journal of Pharmacology Volume 765, 15 October 2015, Pages 188–197 doi:10.1016/j.ejphar.2015.08.037 |
sie 2015 | Inflammatory diseases / JAK/ROCK |
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors - PublicationsPaweł Gunerka, Barbara Dymek, Aleksandra Stanczak, Anna Bujak, Paulina Grygielewicz, Paweł Turowski, Karolina Dzwonek, Monika Lamparska-Przybysz, Tadeusz Pietrucha, Maciej Wieczorek, European Journal of Pharmacology 2015, doi:10.1016/j.ejphar.2015.08.037 |
cze 2015 | Oncology / FGFR |
Analysis of the intra-tumor heterogeneity and consistency between FGFR1 gene amplification and protein expression in squamous cell lung cancer - PostersSkupinska M., Jagus P., Grygielewicz P., Mikolajczyk A., Szczepulska E., Rozy A., Langfort R., Chorostowska-Wynimko J., Wieczorek M., Stanczak A.
|
cze 2015 | Oncology / FGFR |
Preclinical evaluation of a novel, selective pan-FGFR kinase inhibitor CPL-304-110 as a potential anticancer targeted therapy - PostersGrygielewicz P., PiorkowskaN., Mikołajczyk A., Hucz-Kalitowska J.,Yamani A., Dubiel K., Wiecorek M., stanczak A. |
maj 2015 | Inflammatory diseases / JAK/ROCK |
Highly active and selective JAK2 inhibitor CPL-407-220 as a new drug candidate for myeloproliferative disorders - PostersAnna Bujak, Paweł Gunerka1, Joanna Lipner, Michał Mroczkiewicz, Bartosz Stypik, Paweł Turowski, Maciej Wieczorek Posters 1.InnovativeDrugsR&DDepartment, Celon Pharma S.A., Lomianki, Poland; 2. Postgraduate School of Molecular Medicine, Warsaw Medical University,Poland; 3.Department of Medical Biotechnology, Medical University of Lodz, Poland |
kwi 2015 | Inflammatory diseases / JAK/ROCK |
Novel, highly potent and selective JAK3 inhibitor CPL-409-057 disrupting IL-4/IL-13 signaling in asthma therapy - PostersAnna Bujak, Paweł Gunerka, Joanna Lipner, Michał Mroczkiewicz, Bartosz Stypik, Paweł Turowski, Maciej Wieczorek Poster 1.Celon Pharma S.A., Lomianki; 2. Postgraduate School of Molecular Medicine, Warsaw Medical University; 3. Department of Medical Biotechnology, Medical University of Lodz, Poland
|
mar 2015 | Inflammatory diseases / PI3K |
Pharmacokinetics of selective P13K inhibitors after intratracheal instillation in mice - PostersPawel Turowski, Paweł Gunerka, , Joanna Hucz-Kalitowska, Marcin Zagozda, Maciej Dziachan, Mariola Sekular, Anna Bujak,Maciej Wieczorek Poster 11Innovative DrugsR&DDepartment, Celon Pharma S.A., Kielpin, Lomianki, Poland 2Postgraduate Schoolof MolecularMedicine, Warsaw Medical University, Warsaw,Poland 3Department of Medical Biotechnology, Medical University of Lodz, Lodz, Poland |
lis 2014 | Oncology / FGFR |
Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells, - PublicationsGrygielewicz P1, Dymek B, Bujak A, Gunerka P, Stanczak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K, Zdzalik D, Gastric Cancer 2014 Nov 19 |
kwi 2014 | Oncology |
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. - PublicationsZdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K., J Cancer Res Clin Oncol. 2014 Apr;140(4):589-98 |
lut 2014 | Oncology |
Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer - PublicationsBodnar L, Stanczak A, Cierniak S, Smoter M, Cichowicz M, Kozlowski W, Szczylik C, Wieczorek M, Lamparska-Przybysz M. J, Ovarian Res. 2014 Feb 6;7:16. |
gru 2011 | Oncology |
Prognostic significance of Wnt-1, ß-catenin and E-cadherin expression in advanced colorectal carcinoma - PublicationsStanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W, Szczylik C, Pietrucha T, Wieczorek M, Lamparska-Przybysz M, Pathol Oncol Res. 2011 Dec;17(4):955-63. |
gru 2010 | Neuropsychiatry / PDE10A |
In vitro findings of alterations in intracellular calcium homeostasis in schizophrenia - PublicationsBojarski L, Debowska K, Wojda U., Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1367-74. |
lip 2008 | Oncology |
Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells - PublicationsWieczorek M, Paczkowska A, Guzenda P, Majorek M, Bednarek AK, Lamparska-Przybysz M. . Cancer Biol Ther. 2008 Feb;7(2):268-74. |